Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.14
MD's Cash to Debt is ranked higher than
65% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 0.19 vs. MD: 0.14 )
MD' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.14

Equity to Asset 0.76
MD's Equity to Asset is ranked higher than
94% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 0.49 vs. MD: 0.76 )
MD' s 10-Year Equity to Asset Range
Min: 0.64   Max: 0.91
Current: 0.76

0.64
0.91
Interest Coverage 83.50
MD's Interest Coverage is ranked higher than
88% of the 168 Companies
in the Global Medical Care industry.

( Industry Median: 6.11 vs. MD: 83.50 )
MD' s 10-Year Interest Coverage Range
Min: 6.6   Max: 294.93
Current: 83.5

6.6
294.93
F-Score: 4
Z-Score: 6.75
M-Score: -2.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 21.06
MD's Operating margin (%) is ranked higher than
94% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 9.54 vs. MD: 21.06 )
MD' s 10-Year Operating margin (%) Range
Min: 10.23   Max: 27.74
Current: 21.06

10.23
27.74
Net-margin (%) 13.07
MD's Net-margin (%) is ranked higher than
92% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 5.53 vs. MD: 13.07 )
MD' s 10-Year Net-margin (%) Range
Min: 4.52   Max: 16.46
Current: 13.07

4.52
16.46
ROE (%) 13.00
MD's ROE (%) is ranked higher than
84% of the 243 Companies
in the Global Medical Care industry.

( Industry Median: 9.51 vs. MD: 13.00 )
MD' s 10-Year ROE (%) Range
Min: 4.67   Max: 17.59
Current: 13

4.67
17.59
ROA (%) 9.83
MD's ROA (%) is ranked higher than
92% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 4.08 vs. MD: 9.83 )
MD' s 10-Year ROA (%) Range
Min: 3.33   Max: 14.86
Current: 9.83

3.33
14.86
ROC (Joel Greenblatt) (%) 290.96
MD's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 18.48 vs. MD: 290.96 )
MD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 35.94   Max: 727.31
Current: 290.96

35.94
727.31
Revenue Growth (%) 13.10
MD's Revenue Growth (%) is ranked higher than
85% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 7.50 vs. MD: 13.10 )
MD' s 10-Year Revenue Growth (%) Range
Min: 6.9   Max: 45.1
Current: 13.1

6.9
45.1
EBITDA Growth (%) 11.50
MD's EBITDA Growth (%) is ranked higher than
84% of the 171 Companies
in the Global Medical Care industry.

( Industry Median: 6.70 vs. MD: 11.50 )
MD' s 10-Year EBITDA Growth (%) Range
Min: -1.1   Max: 53.8
Current: 11.5

-1.1
53.8
EPS Growth (%) 9.30
MD's EPS Growth (%) is ranked higher than
74% of the 156 Companies
in the Global Medical Care industry.

( Industry Median: 13.80 vs. MD: 9.30 )
MD' s 10-Year EPS Growth (%) Range
Min: -20.6   Max: 71.7
Current: 9.3

-20.6
71.7
» MD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MD Guru Trades in Q4 2013

Steven Cohen 20,600 sh (New)
Vanguard Health Care Fund 805,600 sh (New)
Paul Tudor Jones 9,530 sh (New)
Joel Greenblatt 344,474 sh (+110.1%)
Jean-Marie Eveillard 8,000 sh (unchged)
Mariko Gordon 55,482 sh (-0.59%)
Jeremy Grantham 99,006 sh (-7.47%)
Chuck Royce 1,067,414 sh (-29.5%)
Columbia Wanger 420,000 sh (-69.43%)
» More
Q1 2014

MD Guru Trades in Q1 2014

Jim Simons 5,000 sh (New)
Jeremy Grantham 156,901 sh (+58.48%)
Vanguard Health Care Fund 805,600 sh (unchged)
Jean-Marie Eveillard 8,000 sh (unchged)
Columbia Wanger Sold Out
Steven Cohen Sold Out
Mariko Gordon 54,010 sh (-2.65%)
Chuck Royce 1,015,114 sh (-4.9%)
Joel Greenblatt 157,284 sh (-54.34%)
Paul Tudor Jones 4,000 sh (-58.03%)
» More
Q2 2014

MD Guru Trades in Q2 2014

Jim Simons 29,700 sh (+494%)
Paul Tudor Jones 14,288 sh (+257.2%)
Joel Greenblatt 207,284 sh (+31.79%)
Vanguard Health Care Fund 805,600 sh (unchged)
Jean-Marie Eveillard Sold Out
Mariko Gordon 53,966 sh (-0.08%)
Jeremy Grantham 140,101 sh (-10.71%)
Chuck Royce 883,714 sh (-12.94%)
» More
Q3 2014

MD Guru Trades in Q3 2014

Vanguard Health Care Fund 805,600 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Add 31.79%0.04%$56.36 - $64 $ 61.54%207284
Jean-Marie Eveillard 2014-06-30 Sold Out $56.36 - $64 $ 61.54%0
Joel Greenblatt 2014-03-31 Reduce -54.34%0.24%$52.85 - $63.2 $ 61.56%157284
Joel Greenblatt 2013-12-31 Add 110.1%0.23%$50.21 - $56.305 $ 61.514%344474
Vanguard Health Care Fund 2013-12-31 New Buy0.13%$50.21 - $56.305 $ 61.514%805600
Joel Greenblatt 2013-03-31 Add 55.76%0.13%$39.76 - $44.82 $ 61.543%77224
Andreas Halvorsen 2013-03-31 Sold Out 0.03%$39.76 - $44.82 $ 61.543%0
Andreas Halvorsen 2012-12-31 Reduce -90.44%0.3%$34.25 - $40.68 $ 61.563%60000
Andreas Halvorsen 2012-09-30 Reduce -28.52%0.14%$30.64 - $37.82 $ 61.578%627444
Jean-Marie Eveillard 2012-06-30 Add 33.33%$29.93 - $37.02 $ 61.586%4000
Andreas Halvorsen 2012-03-31 Reduce -22%0.21%$34.04 - $37.73 $ 61.580%1001463
Joel Greenblatt 2012-03-31 Add 49.08%0.12%$34.04 - $37.73 $ 61.580%54416
Jean-Marie Eveillard 2012-03-31 New Buy$34.04 - $37.73 $ 61.580%3000
David Dreman 2011-12-31 Sold Out 0.67%$30.37 - $36.01 $ 61.585%0
Andreas Halvorsen 2011-12-31 Reduce -20.54%0.24%$30.37 - $36.01 $ 61.585%1283863
Joel Greenblatt 2011-12-31 Add 27.86%0.07%$30.37 - $36.01 $ 61.585%36500
Ray Dalio 2011-12-31 Sold Out 0.03%$30.37 - $36.01 $ 61.585%0
David Dreman 2011-09-30 Reduce -20.47%0.15%$29.31 - $36.83 $ 61.585%425379
Ray Dalio 2011-09-30 New Buy0.02%$29.31 - $36.83 $ 61.585%26386
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 20.80
MD's P/E(ttm) is ranked higher than
89% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 37.70 vs. MD: 20.80 )
MD' s 10-Year P/E(ttm) Range
Min: 6.96   Max: 26.65
Current: 20.8

6.96
26.65
P/B 2.56
MD's P/B is ranked higher than
77% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 2.89 vs. MD: 2.56 )
MD' s 10-Year P/B Range
Min: 1.23   Max: 3.59
Current: 2.56

1.23
3.59
P/S 2.71
MD's P/S is ranked higher than
62% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 1.56 vs. MD: 2.71 )
MD' s 10-Year P/S Range
Min: 1.12   Max: 3.84
Current: 2.71

1.12
3.84
PFCF 16.90
MD's PFCF is ranked higher than
87% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 54.38 vs. MD: 16.90 )
MD' s 10-Year PFCF Range
Min: 6.33   Max: 20.73
Current: 16.9

6.33
20.73
EV-to-EBIT 13.30
MD's EV-to-EBIT is ranked higher than
87% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 25.64 vs. MD: 13.30 )
MD' s 10-Year EV-to-EBIT Range
Min: -21.5   Max: 16
Current: 13.3

-21.5
16
PEG 2.04
MD's PEG is ranked higher than
92% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. MD: 2.04 )
MD' s 10-Year PEG Range
Min: 0.6   Max: 2.15
Current: 2.04

0.6
2.15
Shiller P/E 25.53
MD's Shiller P/E is ranked higher than
89% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 96.17 vs. MD: 25.53 )
MD' s 10-Year Shiller P/E Range
Min: 9.77   Max: 35.15
Current: 25.53

9.77
35.15
Current Ratio 1.55
MD's Current Ratio is ranked higher than
76% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 1.40 vs. MD: 1.55 )
MD' s 10-Year Current Ratio Range
Min: 0.77   Max: 11.34
Current: 1.55

0.77
11.34
Quick Ratio 1.55
MD's Quick Ratio is ranked higher than
80% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 1.28 vs. MD: 1.55 )
MD' s 10-Year Quick Ratio Range
Min: 0.77   Max: 11.34
Current: 1.55

0.77
11.34

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.05
MD's Price/DCF (Projected) is ranked higher than
89% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 2.96 vs. MD: 1.05 )
MD' s 10-Year Price/DCF (Projected) Range
Min: 0.46   Max: 3.76
Current: 1.05

0.46
3.76
Price/Median PS Value 1.09
MD's Price/Median PS Value is ranked higher than
85% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 1.23 vs. MD: 1.09 )
MD' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 4.03
Current: 1.09

0.2
4.03
Price/Peter Lynch Fair Value 2.01
MD's Price/Peter Lynch Fair Value is ranked higher than
91% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. MD: 2.01 )
MD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.09   Max: 4.44
Current: 2.01

0.09
4.44
Earnings Yield (Greenblatt) 7.50
MD's Earnings Yield (Greenblatt) is ranked higher than
86% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 4.10 vs. MD: 7.50 )
MD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.2   Max: 18.8
Current: 7.5

6.2
18.8
Forward Rate of Return (Yacktman) 14.02
MD's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 9.78 vs. MD: 14.02 )
MD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 12.8   Max: 31.1
Current: 14.02

12.8
31.1

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:PDC.Germany, MD.Mexico
Mednax Inc, was incorporated in Florida in 2007 and is the successor to Pediatrix, which was incorporated in Florida in 1979. The Company is a provider of physician services including Neonatal Care, Maternal-fetal Care, Pediatric Cardiology Care, Other Pediatric Subspecialty Care and Anesthesia Care. At December 31, 2012, its national network comprised 2,100 affiliated physicians, including 1000 physicians who provide neonatal clinical care, in 34 states and Puerto Rico, primarily within hospital-based neonatal intensive care units ("NICUs"), to babies born prematurely or with medical complications. The Company has 200 affiliated physicians who provide maternal-fetal care to expectant mothers experiencing complicated pregnancies and obstetrical hospitalist services in many areas where its affiliated neonatal physicians practice. The Company's network includes other pediatric subspecialists, including 120 physicians providing pediatric cardiology care, 100 physicians providing pediatric intensive care, 60 physicians providing hospital-based pediatric care and 15 physicians providing pediatric surgical care. In addition, It has 625 physicians who provide anesthesia care to patients in connection with surgical and other procedures as well as pain management. The Company provides clinical care to babies born prematurely or with complications within specific units at hospitals, mainly NICUs, through a team of experienced neonatal physician subspecialists called 'neonatologists', neonatal nurse practitioners and other pediatric clinicians. The Company provides outpatient and inpatient clinical care to expectant mothers and their unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, such as maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers and genetic counselors. It provides inpatient and outpatient pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease as well as adults with congenital heart defects through its affiliated pediatric cardiologist subspecialists and other clinicians such as pediatric nurse practitioners, echocardiographers and other diagnostic technicians, and exercise physiologists. Its network includes pediatric intensivists, who are hospital-based pediatricians with additional education and training in caring for critically ill or injured children and adolescents, and pediatric hospitalists, who are hospital-based pediatricians specializing in inpatient care and management of acutely ill children. The Company provides anesthesia care through a team of experienced physician anesthesiologists, certified registered nurse anesthetists and anesthesia assistants. It has physicians who provide maternal-fetal medical care to expectant mothers experiencing complicated pregnancies and obstetrician hospitalist services in many areas where its affiliated neonatal
» More Articles for MD

Headlines

Articles On GuruFocus.com
Midland Options its Casault and Jouvex Gold Projects to SOQUEM Oct 21 2014 
Midland Acquires a new Property Along a High Grade Gold Corridor in the Labrador Trough With Histori Oct 15 2014 
Midland and Donner Begin Geophysical Work on the Samson Project South of Balmoral's Grasset Discover Oct 15 2014 
Groups of Gurus Hold 10-Year Low P/B Stocks - ATVI, CHL, MD Dec 20 2013 
5 Inexpensive Stocks for Your Portfolio Jan 19 2012 
Health Care Provider Nov 11 2011 
Mednax, a Quality Healthcare Stock to Consider Oct 18 2011 
MEDNAX, INC. (MD) COO / Pediatrix Division David A. Clark sells 7,456 Shares Dec 10 2010 
MEDNAX, INC. (MD) COO / Pediatrix Division David A. Clark sells 2,960 Shares Dec 03 2010 
MEDNAX, INC. (MD) CFO Vivian Lopez-blanco sells 1,850 Shares Nov 05 2010 


More From Other Websites
NYSE stocks posting largest percentage increases Oct 30 2014
MEDNAX Inc Earnings Call scheduled for 10:00 am ET today Oct 30 2014
MEDNAX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 30 2014
Q3 2014 MEDNAX Inc Earnings Release - Before Market Open Oct 30 2014
Mednax beats Street 3Q forecasts Oct 30 2014
Mednax beats Street 3Q forecasts Oct 30 2014
MEDNAX Reports 2014 Third Quarter EPS of $0.86 Oct 30 2014
MEDNAX Announces Acquisition of Anesthesiology Practice in Georgia Oct 29 2014
7:02 am MEDNAX announces acquisition of anesthesiology practice in Georgia; terms not disclosed,... Oct 29 2014
MEDNAX Announces Acquisition of Anesthesiology Practice in Georgia Oct 29 2014
MedData Launches iPhone App to Improve Billing Reconciliation for Surgical Practices Oct 23 2014
MEDNAX Announces Acquisition of Perinatology Practice in Texas Oct 20 2014
MEDNAX Announces Acquisition of Perinatology Practice in Texas Oct 20 2014
MEDNAX 2014 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 30, 2014 Oct 09 2014
Coverage initiated on MEDNAX by Robert W. Baird Oct 09 2014
Putin holds key to Ukraine peace but keeps world guessing Sep 12 2014
MEDNAX Announces Closing of MedData Acquisition Sep 05 2014
MEDNAX to Acquire Leading Revenue Cycle Management Company Aug 18 2014
MEDNAX, INC. Financials Aug 08 2014
Christopher J. Reading, the President and CEO of U.S. Physical Therapy, Inc. (USPH), Interviews with... Aug 04 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK